Ovarian Cancer Survivorship: Follow-Up Questions

Most survivorship pages open with a schedule. This one cannot, and the honest reason is worth stating first.

NCI says there is little guidance about follow-up after the first course of treatment. It goes further. Finding recurrence early by imaging has not been shown to change outcomes. Nor has finding it early through a rising CA-125.

That is not the same as saying follow-up is pointless. It means the gap between visits is local practice, not proven benefit. Asking what a plan is based on is fair. The answer is often experience rather than evidence.

CA-125 dominates the emotional weather of ovarian cancer follow-up. NCI treats it more coolly.

Its specificity and sensitivity are both low. Other cancers can raise it. So can benign gynecologic problems, such as endometriosis. NCI says serial monitoring during treatment for recurrence may be useful. Whether that gives a net benefit has not been determined.

Two practical consequences follow. A single raised value is not a diagnosis. And a number that stays flat while symptoms change is not reassurance.

Treatment used to end. For many people it now continues as a daily tablet.

Three PARP inhibitors are used as maintenance after a complete or partial response to platinum-based chemotherapy. NCI lists their doses:

• Olaparib, 300 mg tablets twice daily.
• Rucaparib, 600 mg twice daily.
• Niraparib, 300 mg once daily.

Those are NCI's reference figures, not a prescription. Niraparib in particular is often begun at a reduced amount depending on weight and platelet count, and any of the three can be stepped down mid-course. Check the label on your own bottle and take what it says.

Each has its own pattern of effects. For olaparib, NCI lists nausea, fatigue, anemia and abdominal pain. For rucaparib, nausea, fatigue, raised liver enzymes and anemia. For niraparib, nausea, fatigue, constipation, high blood pressure and low platelets. All three carry rare cases of myelodysplastic syndrome or acute myeloid leukemia.

This is the part that turns maintenance into a monitoring commitment.

The FDA label for olaparib gives a number. Myelodysplastic syndrome or acute myeloid leukemia occurred in about 1.2% of patients exposed to it. Most of those cases were fatal. The label directs blood monitoring at baseline and monthly after that. It says to stop the drug if either condition is confirmed. It also lists pneumonitis in 1.0% of patients, and blood clots in the veins.

Ordinary count problems matter too. PRIMA tested niraparib. Grade 3 or higher anemia hit 31% of patients. Thrombocytopenia hit 28.7%. Neutropenia hit 12.8%. None were fatal. But 58 of the 307 people who stopped the drug did so because of side effects.

Numb fingers and toes are among the most common lasting complaints, and the trials record them.

One trial compared two paclitaxel schedules. Grade 2 to 4 sensory neuropathy occurred in 26% on the weekly schedule, and 18% on the other. In a separate comparison, cisplatin delivered straight into the abdomen added more nerve damage on top of paclitaxel given into a vein.

NCI notes a downstream effect that rarely gets explained. Neuropathy still present at recurrence may shift the choice of treatment toward other drugs. So nerve damage is not only a symptom to manage. It narrows later options. That is a reason to have it written down rather than tolerated quietly.

Surgical menopause arrives suddenly, and the obvious remedy is not simple here.

NCI lists postmenopausal hormone replacement therapy among the risk factors for ovarian epithelial cancer. Endometriosis and obesity are on the same list. That does not settle whether hormone therapy is right after treatment. It does explain why the answer is not a routine yes. It depends on the tumor type.

NCI reports that about 20% of ovarian cancers are familial. Most of those trace to variants in BRCA1 or BRCA2. Other genes are involved too. Risk is highest for women with two or more first-degree relatives affected. Lynch syndrome is on NCI's risk factor list as well.

For relatives who test positive, NCI states that risk-reducing oophorectomy greatly decreases ovarian cancer risk in high-risk women. That belongs in a genetics clinic. It is also the part of this diagnosis that reaches past the person treated.

The American Cancer Society projects 21,010 new ovarian cancers and 12,450 deaths in the United States in 2026, and SEER carries that estimate. Stage at diagnosis is skewed: 22% localized, 18% regional, 54% distant. Among people diagnosed from 2016 to 2022, five-year relative survival runs 91.9%, 70.1% and 31.5% across those groups.

Those figures explain why recurrence anxiety here is not irrational. They also explain why a follow-up plan with no proven schedule feels harder than it sounds on paper. Uncertainty is the actual clinical situation, not a failure of communication. See fear of recurrence and watching for recurrence.

• What is the follow-up interval here, and what is it based on?
• Is CA-125 being tracked, and what would a rise actually change?
• Would a rise trigger a scan, a change of treatment, or watching?
• If a PARP inhibitor is continuing, when are blood counts drawn?
• What symptoms of low counts should prompt a call between visits?
• Has neuropathy been graded and recorded in the notes?
• Which specific tumor type was this, and does it affect the hormone therapy question?
• Has genetic counseling been arranged, and who in the family should be offered testing?

• NCI PDQ — Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (Health Professional Version)
• NCI PDQ — Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (Patient Version)
• openFDA drug label API — olaparib (LYNPARZA), Warnings and Precautions
• SEER Cancer Stat Facts: Ovarian Cancer